Vise Technologies Inc. Takes Position in Novavax, Inc. $NVAX

Vise Technologies Inc. bought a new position in shares of Novavax, Inc. (NASDAQ:NVAX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,103 shares of the biopharmaceutical company’s stock, valued at approximately $70,000.

A number of other large investors have also recently bought and sold shares of NVAX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Novavax by 2.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock worth $678,000 after buying an additional 2,750 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Novavax by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 33,169 shares of the biopharmaceutical company’s stock worth $213,000 after acquiring an additional 2,780 shares during the period. Signaturefd LLC raised its holdings in shares of Novavax by 47.2% during the second quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 3,122 shares during the last quarter. Monaco Asset Management SAM lifted its position in Novavax by 1.8% during the first quarter. Monaco Asset Management SAM now owns 290,000 shares of the biopharmaceutical company’s stock valued at $1,859,000 after purchasing an additional 5,000 shares during the period. Finally, Federated Hermes Inc. boosted its holdings in Novavax by 11.1% in the first quarter. Federated Hermes Inc. now owns 56,124 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 5,618 shares during the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Analyst Ratings Changes

NVAX has been the subject of a number of recent research reports. B. Riley reiterated a “buy” rating and set a $16.00 price objective (down previously from $18.00) on shares of Novavax in a research note on Monday, November 10th. Wall Street Zen downgraded Novavax from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. TD Cowen lowered their price objective on Novavax from $8.00 to $7.00 and set a “hold” rating on the stock in a research report on Tuesday, November 4th. Cantor Fitzgerald began coverage on shares of Novavax in a report on Friday, October 24th. They set an “overweight” rating and a $18.00 target price for the company. Finally, Bank of America reiterated an “underperform” rating and issued a $7.00 target price (down from $9.00) on shares of Novavax in a research note on Wednesday, August 20th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $11.25.

Novavax Stock Down 3.4%

Shares of NVAX opened at $6.57 on Wednesday. The firm has a market cap of $1.07 billion, a P/E ratio of 2.88, a PEG ratio of 0.12 and a beta of 2.68. Novavax, Inc. has a 12 month low of $5.01 and a 12 month high of $11.55. The stock’s 50 day moving average is $8.30 and its two-hundred day moving average is $7.60. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93.

Novavax (NASDAQ:NVAX) last announced its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.08) by ($0.17). Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The business had revenue of $70.45 million for the quarter, compared to analyst estimates of $55.63 million. During the same period in the previous year, the company earned ($0.76) earnings per share. The company’s quarterly revenue was down 16.7% compared to the same quarter last year. Novavax has set its FY 2025 guidance at EPS. Analysts predict that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.